LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PTN
Palatin Technologies, Inc.
There isn't enough reported data to score PTN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PTN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
PTN's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PTN PE Valuation
PTN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PTN Forward outlook
There aren't enough analyst estimates for PTN to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
PTN Earnings Per Share
PTN and LLY do not have enough comparable growth data to identify a winner.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PTN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PTN on profitability, with a higher operating margin.
PTN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $350K | -80% |
| Q4 2023 | $2M | +98% |
| Q2 2023 | $1.8M | +129% |
| Q1 2023 | $1.2M | +453% |
| Q4 2022 | $1M | +311% |
| Q2 2022 | $770.7K | +340% |
| Q1 2022 | $216.1K | +144% |
PTN's revenue is growing: $300,770 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1469% | N/A |
| Q1 2026 | -40% | N/A |
| Q4 2025 | -6316% | N/A |
| Q3 2025 | 53% | N/A |
| Q2 2024 | -2383% | -1770 points |
| Q4 2023 | 58% | +602 points |
| Q3 2023 | -290% | N/A |
| Q2 2023 | -614% | +1086 points |
PTN's operating margin was −1469% last quarter, up 914 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with PTN at down 23%.
PTN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | +$1.4M |
| Q1 2026 | -$4.5M | +$898.7K |
| Q3 2025 | -$1.6M | +$5.4M |
| Q2 2025 | -$4.1M | +$2.4M |
| Q1 2025 | -$5.4M | +$3.3M |
| Q4 2023 | -$10.5M | +$6.9M |
| Q4 2022 | -$17.4M | -$11M |
| Q3 2022 | -$24.7K | +$6.5M |
PTN has burned cash in almost every quarter: −$13M over the past year, against −$27M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PTN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PTN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +54% | +1.4M shares |
| 1 year | +848% | +3.5M shares |
| 3 years | +1789% | +3.7M shares |
| 5 years | +1978% | +3.7M shares |
| Available history | +2262% | +3.7M shares |
PTN has 4M diluted shares, up 848% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PTN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2020 | -2.5x | Net Cash |
| Q4 2019 | -2.5x | Net Cash |
| Q3 2019 | -2.6x | Net Cash |
| Q2 2019 | -1.2x | Net Cash |
PTN has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PTN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 15.1 | Oversold |
PTN's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PTN PE vs Healthcare Sector
PTN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PTN on trend strength, trading above more of its moving averages.
PTN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.12 | 7.7% below |
| 20 week MA | $8.79 | 25% below |
| 50 week MA | $14.4 | 54% below |
| 100 week MA | $17.7 | 63% below |
| 200 week MA | $63.0 | 90% below |
PTN is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PTN on returns for 2026, with the stronger performance.
PTN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,000.0 | $837.5 | -16% |
| 2021 | $837.5 | $650.0 | -22% |
| 2022 | $650.0 | $118.0 | -82% |
| 2023 | $118.0 | $199.0 | +69% |
| 2024 | $199.0 | $55.5 | -72% |
| 2025 | $55.5 | $14.6 | -74% |
| 2026 YTD | $14.6 | $6.57 | -55% |
PTN has finished lower in five of the last six years. It's down 55% so far in 2026.